Related Experiment Videos

TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3

Xiaomin Mu1, Chawnshang Chang

  • 1Department of Pathology, George Whipple Laboratory for Cancer Research, Urology, Radiation Oncology, New York, NY, USA.

The Prostate
|September 2, 2003
PubMed
Abstract

Insights

Orphan nuclear receptor TR2 suppresses androgen receptor (AR) activity in prostate cancer cells. This interaction may offer new ways to control AR function and treat prostate cancer.

Area of Science:

  • Molecular Endocrinology
  • Cancer Biology
  • Nuclear Receptor Signaling

Background:

  • Androgen receptor (AR) and orphan receptor TR2 (TR2) are nuclear receptors found in prostate cancer.
  • AR drives prostate cancer progression, while TR2's role remains unclear.

Purpose of the Study:

  • To investigate the function of TR2 in prostate cancer.
  • To determine the relationship between TR2 and AR in prostate cancer.

Main Methods:

  • Transient transfection and CAT reporter gene assays for AR transactivation.
  • Northern blot analysis for prostate specific antigen (PSA) expression.
  • Glutathione-S-transferase (GST) pull-down and mammalian two-hybrid assays for AR-TR2 interaction.

Main Results:

  • TR2 suppressed AR-mediated transactivation and PSA expression in prostate cancer cells.
  • TR2's suppression mechanism involves interaction with AR, not coregulator competition.

Conclusions:

  • TR2 acts as a negative modulator of AR function in prostate cancer.
  • Targeting TR2 could offer a novel strategy for modulating AR in prostate cancer treatment.

Related Concept Videos